AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29079405 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive condition participants received compensation for taking counseling calls ($30 per call) and for biochemically verified abstinence at the 6-month visit ($40).
Number of subjects: 1900
Study 29079405 — intervention group
Group type: COMPARATOR
Intervention: Control participants received no incentive payments.
Number of subjects: 1900
Study 29079405 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive condition participants accepted Wisconsin Tobacco Quit Line treatment calls.
Number of subjects: 1900
Study 29079405 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive participants had a cost/quit/participant of $3,601.37.
Number of subjects: 1900
Study 26536471 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo oxygen inhaled through a mask
Number of subjects: 0
Study 26536471 — intervention group
Group type: COMPARATOR
Intervention: Placebo aspirin swallowed with a pill
Number of subjects: 0
Study 23524858 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% (8 PM)
Number of subjects: 68
Study 23524858 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% (or 0.25% for those <3 y old; 8 AM/8 PM)
Number of subjects: 68
Study 20091317 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized progesterone (100 mg) administered daily by vaginal suppository between 24 and 34 weeks of gestation
Number of subjects: 150
Study 20091317 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 mg) administered daily by vaginal suppository between 24 and 34 weeks of gestation
Number of subjects: 150
Study 19863881 — intervention group
Group type: EXPERIMENTAL
Intervention: HX575
Number of subjects: 0
Study 19863881 — intervention group
Group type: COMPARATOR
Intervention: Comparator epoetin‐a
Number of subjects: 0
Study 17326893 — intervention group
Group type: EXPERIMENTAL
Intervention: Ophthalmic erythromycin ointment (0.5%)
Number of subjects: 138
Study 17326893 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline (one drop into each eye)
Number of subjects: 138
Study 17326893 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 138
Study 14748035 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian hierarchical modelling approach for binary outcome data
Number of subjects: 0
Study 14748035 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorporation of prior data about typical ICCs
Number of subjects: 0
Study 14748035 — intervention group
Group type: EXPERIMENTAL
Intervention: Consideration of both cluster and individual level covariates
Number of subjects: 0
Study 12087649 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-coated pacifier
Number of subjects: 84
Study 12087649 — intervention group
Group type: COMPARATOR
Intervention: Water-moistened pacifier
Number of subjects: 84
Study 12087649 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 84
Study 12087649 — intervention group
Group type: COMPARATOR
Intervention: Oral sucrose solution
Number of subjects: 84
Study 9793772 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% diclofenac plus 0.3% tobramycin ophthalmic solution (two eyedrops every 6 hours, n = 44)
Number of subjects: 88
Study 9793772 — intervention group
Group type: COMPARATOR
Intervention: 0.1% diclofenac (Voltaren) plus 0.3% tobramycin (Tobrex) (one drop of each every 6 hours, n = 44)
Number of subjects: 88
Study 7643263 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric indwelling feeding tubes (placed for up to 3 days)
Number of subjects: 93
Study 7643263 — intervention group
Group type: COMPARATOR
Intervention: Orogastric intermittent feeding tubes (placed for each feeding and removed after feeding)
Number of subjects: 93
Study 2653395 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium slow release (DSR) 100 mg daily
Number of subjects: 846
Study 2653395 — intervention group
Group type: COMPARATOR
Intervention: Dextropropoxyphene 180 mg and Paracetamol 1.95 g daily (D&P)
Number of subjects: 846
Study 407818 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 95
Study 31823063 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (4 mg/kg)
Number of subjects: 17
Study 31823063 — intervention group
Group type: COMPARATOR
Intervention: Placebo (300 mg of corn-starch)
Number of subjects: 17
Study 27935736 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 3876
Study 27935736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3876
Study 26247388 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional Bias (AB) for alcohol-related stimuli
Number of subjects: 50
Study 26247388 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic Approach/Avoidance tendencies (AA)
Number of subjects: 50
Study 26247388 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 50
Study 23884037 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of lipophilic statins
Number of subjects: 43810
Study 23884037 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (lipophilic statin)
Number of subjects: 43810
Study 23884037 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (lipophilic statin)
Number of subjects: 43810
Study 23884037 — intervention group
Group type: COMPARATOR
Intervention: Hydrophilic statins
Number of subjects: 43810
Study 23884037 — intervention group
Group type: COMPARATOR
Intervention: Long-term use of statins (lipophilic or hydrophilic)
Number of subjects: 43810
Study 21493058 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week adjuvant high-dose interferon α-2b (arm A: 15 × 10(6)U/m(2)d1-5/w × 4w)
Number of subjects: 158
Study 21493058 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year adjuvant high-dose interferon α-2b (arm B: 15 × 10(6)U/m(2)d1-5/w × 4w + 9 × 10(6)Utiw × 48w)
Number of subjects: 158
Study 21493058 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 158
Study 19643849 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent crossclamp fibrillation
Number of subjects: 195
Study 19643849 — intervention group
Group type: COMPARATOR
Intervention: Cardioplegic arrest
Number of subjects: 195
Study 19643849 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 195
Study 17606328 — intervention group
Group type: EXPERIMENTAL
Intervention: High cortisol responders exposed to acute psychosocial stress (Trier Social Stress Test)
Number of subjects: 20
Study 17606328 — intervention group
Group type: COMPARATOR
Intervention: Low cortisol responders exposed to acute psychosocial stress (Trier Social Stress Test)
Number of subjects: 20
Study 17606328 — intervention group
Group type: COMPARATOR
Intervention: Participants in a rest condition (control)
Number of subjects: 20
Study 15134765 — intervention group
Group type: EXPERIMENTAL
Intervention: Unexpected disruption consisting of a brief low spatial frequency motion field during the events.
Number of subjects: 0
Study 15134765 — intervention group
Group type: EXPERIMENTAL
Intervention: Blank-screen disruptions added in the second experiment.
Number of subjects: 0
Study 12122965 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg daily)
Number of subjects: 37
Study 9040545 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (60 mg)
Number of subjects: 900
Study 9040545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 900
Study 8424280 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2 mg.kg‐1 i.v.)
Number of subjects: 20
Study 8424280 — intervention group
Group type: COMPARATOR
Intervention: Intralipid 10%
Number of subjects: 20
Study 8424280 — intervention group
Group type: COMPARATOR
Intervention: Flunitrazepam (0.03 mg.kg‐1 i.v.)
Number of subjects: 20
Study 3305896 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite cement in mechanically corrugated post spaces
Number of subjects: 0
Study 3305896 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite cement in post spaces rinsed with 1 ml of 17% EDTA and 1 ml of 5.25% NaOCl
Number of subjects: 0
Study 3305896 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc phosphate cement in mechanically corrugated post spaces
Number of subjects: 0
Study 3305896 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass-ionomer cement in post spaces irrigated with 1 ml of 40% polyacrylic acid and rinsed with distilled water
Number of subjects: 0
Study 30078504 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial telephone counseling (PTC)
Number of subjects: 204
Study 30078504 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 204
Study 26826533 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram treatment for 6 weeks
Number of subjects: 53
Study 24632986 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced retrieval combined with errorless learning (SR/EL)
Number of subjects: 61
Study 24632986 — intervention group
Group type: COMPARATOR
Intervention: Spaced retrieval only (SR-only)
Number of subjects: 61
Study 22544598 — intervention group
Group type: EXPERIMENTAL
Intervention: Myth and Denial program session
Number of subjects: 211
Study 22544598 — intervention group
Group type: EXPERIMENTAL
Intervention: Program-delayed assessment group
Number of subjects: 211
Study 22544598 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 211
Study 21341623 — intervention group
Group type: EXPERIMENTAL
Intervention: Group RD (100 microg dexmedetomidine + 19 ml of 0.25% ropivacaine)
Number of subjects: 60
Study 21341623 — intervention group
Group type: COMPARATOR
Intervention: Group R (19 ml of 0.25% ropivacaine + 1 ml isotonic saline)
Number of subjects: 60
Study 21341623 — intervention group
Group type: EXPERIMENTAL
Intervention: Group RD
Number of subjects: 60
Study 17609908 — intervention group
Group type: EXPERIMENTAL
Intervention: Quyu Jiedu Recipe (QJR)
Number of subjects: 50
Study 17609908 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestrinone (GT)
Number of subjects: 50
Study 17609908 — intervention group
Group type: COMPARATOR
Intervention: Normal control group (healthy women)
Number of subjects: 50
Study 16130860 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide (Platinum/Colgate)
Number of subjects: 30
Study 16130860 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% hydrogen peroxide (Day White 2Z/Discus Dental)
Number of subjects: 30
Study 11999466 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg once daily (o.d.)
Number of subjects: 311
Study 10411249 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygenator coated with albumin in the priming solution
Number of subjects: 60
Study 10411249 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygenator coated with Carmeda
Number of subjects: 60
Study 10411249 — intervention group
Group type: COMPARATOR
Intervention: Uncoated oxygenator (noncoated group)
Number of subjects: 60
Study 7547213 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg i.v. 30 min after cisplatin or 16 mg orally at the end of cisplatin infusion)
Number of subjects: 0
Study 7547213 — intervention group
Group type: COMPARATOR
Intervention: Buspirone (60 mg p.o. at the end of cisplatin and 60 mg p.o., 30 min later)
Number of subjects: 0
Study 1372924 — intervention group
Group type: EXPERIMENTAL
Intervention: Large volume paracentesis (LVP) and infusion of low molecular weight dextran (n = 20)
Number of subjects: 40
Study 1372924 — intervention group
Group type: COMPARATOR
Intervention: Aldactone 400 mg/day and furosemide 80 mg/day (n = 20)
Number of subjects: 40
Study 3895014 — intervention group
Group type: EXPERIMENTAL
Intervention: DGAVP 92 micrograms intranasally TID
Number of subjects: 17
Study 3895014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 29310015 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training with instability (RTI)
Number of subjects: 39
Study 29310015 — intervention group
Group type: COMPARATOR
Intervention: Resistance training (RT)
Number of subjects: 39
Study 29310015 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising control
Number of subjects: 39
Study 27741007 — intervention group
Group type: COMPARATOR
Intervention: Total Parathyroidectomy (TPTX)
Number of subjects: 100
Study 27741007 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Parathyroidectomy with Autotransplantation (TPTX+AT)
Number of subjects: 100
Study 25482346 — intervention group
Group type: EXPERIMENTAL
Intervention: ScorpioFlex TKA
Number of subjects: 15
Study 25482346 — intervention group
Group type: COMPARATOR
Intervention: NRG TKA
Number of subjects: 15
Study 23997131 — intervention group
Group type: EXPERIMENTAL
Intervention: Synovectomy
Number of subjects: 187
Study 23997131 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 187
Study 21875548 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0
Study 21875548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18500080 — intervention group
Group type: EXPERIMENTAL
Intervention: PRK with MMC 0.002% for 1 minute
Number of subjects: 44
Study 18500080 — intervention group
Group type: EXPERIMENTAL
Intervention: PRK with MMC
Number of subjects: 44
Study 18500080 — intervention group
Group type: COMPARATOR
Intervention: LASIK
Number of subjects: 44
Study 16805745 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 661
Study 16805745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 661
Study 14725412 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg elemental zinc as zinc sulphate)
Number of subjects: 300
Study 14725412 — intervention group
Group type: COMPARATOR
Intervention: Control group (no zinc supplementation)
Number of subjects: 300
Study 12212254 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30
Study 12212254 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 30
Study 12212254 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 7581831 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (300 mg)
Number of subjects: 0
Study 7581831 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (250 mg)
Number of subjects: 0
Study 7581831 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (15 mg)
Number of subjects: 0
Study 7581831 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined supplement (vitamin E, vitamin C, beta-carotene)
Number of subjects: 0
Study 2207401 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion after parasympathetic blockade with 30 micrograms/kg intravenous atropine
Number of subjects: 21
Study 2207401 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion before atropine administration
Number of subjects: 21
Study 6996506 — intervention group
Group type: EXPERIMENTAL
Intervention: Early fiberoptic endoscopy with immediate results
Number of subjects: 95
Study 6996506 — intervention group
Group type: COMPARATOR
Intervention: Early fiberoptic endoscopy with results revealed after 4 days
Number of subjects: 95
Study 31614535 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory of planned behavior (TPB)-based health education intervention with a planning strategy (one-on-one counseling session with a planning sheet)
Number of subjects: 297
Study 31614535 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory of planned behavior (TPB)-based health education intervention with a planning strategy
Number of subjects: 297
Study 31614535 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) received a leaflet only
Number of subjects: 297
Study 28520668 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 22
Study 28520668 — intervention group
Group type: COMPARATOR
Intervention: Stretching comparison
Number of subjects: 22
Study 28520668 — intervention group
Group type: COMPARATOR
Intervention: Healthy comparison group
Number of subjects: 22
Study 26633093 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching by medical assistants
Number of subjects: 441
Study 26633093 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 441
Study 23734871 — intervention group
Group type: EXPERIMENTAL
Intervention: Junior Doctor Dashboard providing feedback on prescription warning information and laboratory alerting acceptance rates, accessed weekly for 4 months.
Number of subjects: 86
Study 23734871 — intervention group
Group type: COMPARATOR
Intervention: Control group (no automated feedback).
Number of subjects: 86
Study 21770020 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital anomalies identified at birth
Number of subjects: 2365
Study 21770020 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital anomalies identified at 6-week postnatal visit
Number of subjects: 2365
Study 21770020 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital anomalies identified at illness-related visits
Number of subjects: 2365
Study 21770020 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of major congenital anomalies
Number of subjects: 2365
Study 21770020 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of cardiac anomalies
Number of subjects: 2365
Study 21770020 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of neural system anomalies
Number of subjects: 2365
Study 21770020 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of musculoskeletal anomalies
Number of subjects: 2365
Study 21770020 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of skin anomalies
Number of subjects: 2365
Study 19318792 — intervention group
Group type: EXPERIMENTAL
Intervention: SNAPPS training
Number of subjects: 64
Study 19318792 — intervention group
Group type: COMPARATOR
Intervention: Feedback training
Number of subjects: 64
Study 19318792 — intervention group
Group type: COMPARATOR
Intervention: Usual-and-customary instruction
Number of subjects: 64
Study 17046377 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel (150 mug)
Number of subjects: 52
Study 17046377 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (100 mug)
Number of subjects: 52
Study 17046377 — intervention group
Group type: COMPARATOR
Intervention: Control group (36 women)
Number of subjects: 52
Study 12894131 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept (12 weekly intramuscular or intravenous injections)
Number of subjects: 1300
Study 12894131 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept (2 courses)
Number of subjects: 1300
Study 12894131 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept (single course)
Number of subjects: 1300
Study 12894131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1300
Study 10703113 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBMP-2/collagen sponge
Number of subjects: 14
Study 10703113 — intervention group
Group type: COMPARATOR
Intervention: autogenous iliac crest bone
Number of subjects: 14
Study 10178675 — intervention group
Group type: EXPERIMENTAL
Intervention: Belgian blood donors
Number of subjects: 0
Study 10178675 — intervention group
Group type: COMPARATOR
Intervention: Tunisian blood donors
Number of subjects: 0
Study 10178675 — intervention group
Group type: EXPERIMENTAL
Intervention: Both populations
Number of subjects: 0
Study 7678844 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon monoxide exposure (3% COHb)
Number of subjects: 33
Study 7678844 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon monoxide exposure (5% COHb)
Number of subjects: 33
Study 7678844 — intervention group
Group type: COMPARATOR
Intervention: Room air (control)
Number of subjects: 33
Study 7678844 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 33
Study 3301455 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% desoxymethasone
Number of subjects: 96
Study 3301455 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% desoxymethasone
Number of subjects: 96
Study 3301455 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% betamethasone valerate
Number of subjects: 96
Study 3301455 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% hydrocortisone
Number of subjects: 96
Study 29431561 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training
Number of subjects: 37
Study 29431561 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral muscle training
Number of subjects: 37
Study 29431561 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study 26826274 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential media (Quinn's Advantage Cleavage Medium followed by Blast Assist)
Number of subjects: 192
Study 26826274 — intervention group
Group type: COMPARATOR
Intervention: Monophasic medium (Continuous Single Culture)
Number of subjects: 192
Study 26826274 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential media
Number of subjects: 192
Study 26826274 — intervention group
Group type: COMPARATOR
Intervention: Monophasic medium
Number of subjects: 192
Study 25532586 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Saccharum iron (200 mg/dose, once a week for 5 weeks, total 1000 mg)
Number of subjects: 38
Study 25532586 — intervention group
Group type: COMPARATOR
Intervention: High-dose Saccharum iron (500 mg/dose, once every two weeks for 4 weeks, total 1000 mg)
Number of subjects: 38
Study 24324379 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality-cognitive rehabilitation (VR-CR) intervention
Number of subjects: 4
Study 24324379 — intervention group
Group type: COMPARATOR
Intervention: Control test
Number of subjects: 4
Study 20634296 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary Albumin Excretion (UAE)
Number of subjects: 701
Study 20634296 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary Protein Excretion (UPE)
Number of subjects: 701
Study 20634296 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary Albumin Concentration (UAC)
Number of subjects: 701
Study 20634296 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin:Creatinine Ratio (ACR)
Number of subjects: 701
Study 18340485 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 1256
Study 18340485 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1256
Study 16888046 — intervention group
Group type: EXPERIMENTAL
Intervention: ISC+EX (ischemia with low-intensity exercise)
Number of subjects: 9
Study 16888046 — intervention group
Group type: EXPERIMENTAL
Intervention: ISC (ischemia alone)
Number of subjects: 9